3-chloro-2-methylbenzothiophene | 64845-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-chloro-2-methylbenzothiophene
• 英文别名: 3-chloro-2-methyl-benzo[b]thiophene；3-Chloro-2-methyl-benzo[b]thiophene；3-chloro-2-methyl-1-benzothiophene
• CAS: 64845-10-9
• 化学式: C₉H₇ClS
• 分子量: 182.674
• InChiKey: WZSQNMZHCUHQMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基苯并噻吩 在 氧气 、 lithium chloride 、 copper dichloride 作用下， 以 溶剂黄146 为溶剂， 110.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以63%的产率得到3-chloro-2-methylbenzothiophene
  参考文献：
  名称：

  Regioselective copper-catalyzed chlorination and bromination of arenes with O2 as the oxidant

  摘要：

  在CuX2、LiX（X = Cl，Br）和氧气存在下，富电子芳香C-H键会发生区域选择性氯化和溴化。初步的机理洞察表明，溴化和氯化反应通过不同的途径进行。

  DOI：

  10.1039/b915487f

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010137738A1

  公开（公告）日：2010-12-02

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新颖的杂环化合物。一种由通式（1）表示的杂环化合物，其中，R1和R2分别独立表示氢；苯基较低烷基基团，可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基；或环C3-C8烷基较低烷基基团；或类似物；R3表示较低炔基基团或类似物；R4表示可能具有从1,3,4-噁二唑基团（例如，卤素）或从吡啶基团等组成的取代基的苯基团；所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
• THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS
  申请人：Allergan, Inc.

  公开号：US20150329518A1

  公开（公告）日：2015-11-19

  Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.

  本文描述了可以用于局部液体、乳霜或其他剂型（如固体）中的化合物，用于降低眼内压、治疗青光眼、促进头发生长、治疗伤口或其他医疗和/或化妆用途。
• [EN] SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS SPIROCYCLIQUES ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI
  申请人：ABIDE THERAPEUTICS INC

  公开号：WO2019046318A1

  公开（公告）日：2019-03-07

  Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

  本文提供的化合物和组合物可用作MAGL的调节剂。此外，这些化合物和组合物可用于治疗疼痛。
• BENGAMIDES WITH A SUBSTITUTED CAPROLACTAME CYCLE, METHOD FOR THE PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF
  申请人：Zhang Jidong

  公开号：US20070249584A1

  公开（公告）日：2007-10-25

  The invention relates to the preparation of substituted caprolactams, a method for the preparation thereof, compositions containing them and the use thereof as a medicament, particularly as anticancer agents.

  这项发明涉及取代环己内酰胺的制备，制备方法，包含它们的组合物以及将其用作药物，特别是抗癌剂的用途。
• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。